Publications

1. Indacaterol/glycopyrronium/mometasone (Enerzair® Breezhaler®) for maintenance treatment of asthma in adult patients

   The National Health Care Institute has completed its assessment whether Indacaterol/glycopyrronium/mometasone (Enerzair® ...

   Report | 24-09-2020

2. Indacaterol acetate/mometasone furoate (Atectura® Breezhaler®) for the maintenance treatment for asthma in adults and adolescents of 12 years and older

   The National Health Care Institute has completed its assessment whether indacaterol acetate/mometasone furoate (Atectura® ...

   Report | 24-09-2020

3. Osimertinib (Tagrisso®) for the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) with an epidermal growth factor receptor (EGFR) mutation (reassessment)

   The Minister of Medical Care has requested the National Health Care Institute to reassess whether osimertinib (Tagrisso®) for the ...

   Report | 21-09-2020

4. Avelumab (Bavencio®) in combination with axitinib as a first-line treatment for adult patients with advanced renal cell carcinoma

   The National Health Care Institute has completed its assessment whether avelumab (Bavencio®) in combination with axitinib can be ...

   Report | 21-09-2020

5. GVS assessment of ivacaftor/tezacaftor (Symkevi®) in combination with ivacaftor (Kalydeco®) for the treatment of cystic fibrosis

   The National Health Care Institute completed its assessment whether an extension is possible of the conditions of List 2 of the ...

   Report | 17-08-2020

6. Ibrutinib (Imbruvica®) for the treatment of Waldenstrom's disease

   The National Health Care Institute has completed its assessment whether ibrutinib (Imbruvica®) for the treatment of adult ...

   Report | 03-07-2020

7. Ibrutinib (Imbruvica®) for the treatment of adult patients with previously untreated chronic lymphatic leukaemia (CLL)

   The National Health Care Institute has completed its assessment whether ibrutinib (Imbruvica®) for the treatment of adult ...

   Report | 03-07-2020

8. GVS assessment of Trifarotene (50 microgram/gram cream) (Aklief®) for the cutaneous treatment of acne vulgaris on the face and torso in patients aged 12 years and over

   The National Health Care Institute has completed its assessment whether trifarotene (50 microgram/gram cream) (Aklief®) for the ...

   Report | 11-06-2020

9. Package advice dabrafenib/trametinib (Tafinlar®/Mekinist®)

   Zorginstituut Nederland has completed its reassessment of the pharmaco-economic analysis of dabrafenib in combination with ...

   Report | 02-06-2020

10. International strategic agenda 2020 National Health Care Institute

    The international strategic agenda 2020 describes the international activities of the National Health Care Institute ...

    Publication | 31-05-2020